Discovery of phosphodiesterase-4 inhibitors: Serendipity and rational drug design

Susanne C Feil, Jessica K Holien, Craig James Morton, Nancy C Hancock, Philip Thompson, Michael William Parker

Research output: Contribution to journalArticleResearchpeer-review

2 Citations (Scopus)

Abstract

Phosphodiesterase 4 (PDE4), the primary cyclic AMP-hydrolysing enzyme in cells, is a promising drug target for a wide range of mental disorders including Alzheimer s and Huntington s diseases, schizophrenia, and depression, plus a range of inflammatory diseases including chronic obstructive pulmonary disease, asthma, and rheumatoid arthritis. However, targeting PDE4 is complicated by the fact that the enzyme is encoded by four very closely related genes, together with 20 distinct isoforms as a result of mRNA splicing, and inhibition of some of these isoforms leads to intolerable side effects in clinical trials. With almost identical active sites between the isoforms, X-ray crystallography has played a critical role in the discovery and development of safer PDE4 inhibitors. Here we describe our discovery of a novel class of highly potent PDE4 via a virtuous cycle of structure-based drug design and serendipity.
Original languageEnglish
Pages (from-to)1780 - 1785
Number of pages6
JournalAustralian Journal of Chemistry
Volume67
Issue number12
DOIs
Publication statusPublished - 2014

Cite this

Feil, Susanne C ; Holien, Jessica K ; Morton, Craig James ; Hancock, Nancy C ; Thompson, Philip ; Parker, Michael William. / Discovery of phosphodiesterase-4 inhibitors: Serendipity and rational drug design. In: Australian Journal of Chemistry. 2014 ; Vol. 67, No. 12. pp. 1780 - 1785.
@article{47913d0efda24f48b4f8c4dc02d59089,
title = "Discovery of phosphodiesterase-4 inhibitors: Serendipity and rational drug design",
abstract = "Phosphodiesterase 4 (PDE4), the primary cyclic AMP-hydrolysing enzyme in cells, is a promising drug target for a wide range of mental disorders including Alzheimer s and Huntington s diseases, schizophrenia, and depression, plus a range of inflammatory diseases including chronic obstructive pulmonary disease, asthma, and rheumatoid arthritis. However, targeting PDE4 is complicated by the fact that the enzyme is encoded by four very closely related genes, together with 20 distinct isoforms as a result of mRNA splicing, and inhibition of some of these isoforms leads to intolerable side effects in clinical trials. With almost identical active sites between the isoforms, X-ray crystallography has played a critical role in the discovery and development of safer PDE4 inhibitors. Here we describe our discovery of a novel class of highly potent PDE4 via a virtuous cycle of structure-based drug design and serendipity.",
author = "Feil, {Susanne C} and Holien, {Jessica K} and Morton, {Craig James} and Hancock, {Nancy C} and Philip Thompson and Parker, {Michael William}",
year = "2014",
doi = "10.1071/CH14397",
language = "English",
volume = "67",
pages = "1780 -- 1785",
journal = "Australian Journal of Chemistry",
issn = "0004-9425",
publisher = "CSIRO Publishing",
number = "12",

}

Discovery of phosphodiesterase-4 inhibitors: Serendipity and rational drug design. / Feil, Susanne C; Holien, Jessica K; Morton, Craig James; Hancock, Nancy C; Thompson, Philip; Parker, Michael William.

In: Australian Journal of Chemistry, Vol. 67, No. 12, 2014, p. 1780 - 1785.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Discovery of phosphodiesterase-4 inhibitors: Serendipity and rational drug design

AU - Feil, Susanne C

AU - Holien, Jessica K

AU - Morton, Craig James

AU - Hancock, Nancy C

AU - Thompson, Philip

AU - Parker, Michael William

PY - 2014

Y1 - 2014

N2 - Phosphodiesterase 4 (PDE4), the primary cyclic AMP-hydrolysing enzyme in cells, is a promising drug target for a wide range of mental disorders including Alzheimer s and Huntington s diseases, schizophrenia, and depression, plus a range of inflammatory diseases including chronic obstructive pulmonary disease, asthma, and rheumatoid arthritis. However, targeting PDE4 is complicated by the fact that the enzyme is encoded by four very closely related genes, together with 20 distinct isoforms as a result of mRNA splicing, and inhibition of some of these isoforms leads to intolerable side effects in clinical trials. With almost identical active sites between the isoforms, X-ray crystallography has played a critical role in the discovery and development of safer PDE4 inhibitors. Here we describe our discovery of a novel class of highly potent PDE4 via a virtuous cycle of structure-based drug design and serendipity.

AB - Phosphodiesterase 4 (PDE4), the primary cyclic AMP-hydrolysing enzyme in cells, is a promising drug target for a wide range of mental disorders including Alzheimer s and Huntington s diseases, schizophrenia, and depression, plus a range of inflammatory diseases including chronic obstructive pulmonary disease, asthma, and rheumatoid arthritis. However, targeting PDE4 is complicated by the fact that the enzyme is encoded by four very closely related genes, together with 20 distinct isoforms as a result of mRNA splicing, and inhibition of some of these isoforms leads to intolerable side effects in clinical trials. With almost identical active sites between the isoforms, X-ray crystallography has played a critical role in the discovery and development of safer PDE4 inhibitors. Here we describe our discovery of a novel class of highly potent PDE4 via a virtuous cycle of structure-based drug design and serendipity.

UR - http://www.publish.csiro.au/?act=view_file&file_id=CH14397.pdf

U2 - 10.1071/CH14397

DO - 10.1071/CH14397

M3 - Article

VL - 67

SP - 1780

EP - 1785

JO - Australian Journal of Chemistry

JF - Australian Journal of Chemistry

SN - 0004-9425

IS - 12

ER -